Jonathan M Day

US Patent:

8450270, May 28, 2013

Filed:

Jun 16, 2009

Appl. No.:

12/999284

Inventors:

Richard D. Dimarchi - Carmel IN, US
David L. Smiley - Bloomington IN, US
Maria Dimarchi - Carmel IN, US
Joseph Chabenne - Fishers IN, US
Jonathan Day - Bloomington IN, US

Assignee:

Indiana University Research and Technology Corporation - Indianapolis IN

International Classification:

A61K 35/00

US Classification:

514 68, 514 69, 514 117

Abstract:

Modified glucagon peptides are disclosed having improved solubility and/or half-life while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, or both to further enhance the solubility of the glucagon agonist analogs.

US Patent:

8546327, Oct 1, 2013

Filed:

Jun 16, 2009

Appl. No.:

12/999283

Inventors:

Richard D. Dimarchi - Carmel IN, US
David L. Smiley - Bloomington IN, US
Maria Dimarchi - Carmel IN, US
Joseph Chabenne - Fishers IN, US
Jonathan Day - Bloomington IN, US
James Patterson - Martinsville IN, US
Brian Ward - Lebanon IN, US

Assignee:

Indiana University Research and Technology Corporation - Indianapaolis IN

International Classification:

A61K 38/26
A61K 38/00
A61K 38/16

US Classification:

514 72, 514 69, 514 48, 514 213, 530324, 530308, 530345

Abstract:

Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).

US Patent:

20130090286, Apr 11, 2013

Filed:

Aug 6, 2012

Appl. No.:

13/567858

Inventors:

Elisabetta Bianchi - Pomezia, IT
Antonello Pessi - Pomezia, IT
Jonathan Day - Carmel IN, US
Richard Dimarchi - Carmel IN, US
David Smiley - Bloomington IN, US

International Classification:

C07K 14/605

US Classification:

514 53, 530308, 514 117, 514 68, 514 72

Abstract:

Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).

US Patent:

20210147530, May 20, 2021

Filed:

Jan 19, 2021

Appl. No.:

17/152174

Inventors:

- Indianapolis IN, US
Jonathan Wesley Day - Indianapolis IN, US
Robert John Konrad - Carmel IN, US
Yuewei Qian - Carmel IN, US
Oliver Schroeder - Encinitas CA, US
Robert William Siegel - Fountaintown IN, US

International Classification:

C07K 16/22
A61P 3/00

Abstract:

Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.

US Patent:

20200390865, Dec 17, 2020

Filed:

Jun 5, 2020

Appl. No.:

16/893498

Inventors:

- Indianapolis IN, US
John Michael Beals - Indianapolis IN, US
Jonathan Wesley Day - Carmel IN, US
Craig Duane Dickinson - San Diego CA, US
Andrew Ihor Korytko - Oceanside CA, US
Gregory Alan Lazar - Pacifica CA, US

International Classification:

A61K 38/28
C07K 14/62
A61K 38/16
A61K 38/26
C07K 14/00

Abstract:

The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.

US Patent:

20200199212, Jun 25, 2020

Filed:

Dec 13, 2019

Appl. No.:

16/713187

Inventors:

- Indianapolis IN, US
Jonathan Wesley Day - Carmel IN, US
Robert John Konrad - Carmel IN, US
Yuewei Qian - Carmel IN, US
Oliver Schroeder - Encinitas CA, US
Robert William Siegel - Fountaintown IN, US

International Classification:

C07K 16/22

Abstract:

Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodes bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.

US Patent:

20200199213, Jun 25, 2020

Filed:

Dec 13, 2019

Appl. No.:

16/713280

Inventors:

- Indianapolis IN, US
Jonathan Wesley Day - Carmel IN, US
Robert John Konrad - Carmel IN, US
Yuewei Qian - Carmel IN, US
Oliver Schroeder - Encinitas CA, US
Robert William Siegel - Fountaintown IN, US

International Classification:

C07K 16/22
A61P 3/00

Abstract:

Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.

US Patent:

20180177851, Jun 28, 2018

Filed:

Nov 22, 2017

Appl. No.:

15/820608

Inventors:

- Indianapolis IN, US
John Michael Beals - Indianapolis IN, US
Jonathan Wesley Day - Carmel IN, US
Craig Duane Dickinson - San Diego CA, US
Andrew Ihor Korytko - Oceanside CA, US
Gregory Alan Lazar - Pacifica CA, US

International Classification:

A61K 38/28
C07K 14/00
A61K 38/16
C07K 14/62
A61K 38/26
A61K 38/00

Abstract:

The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.